Bicara Therapeutics, Inc. vs. The John Hopkins University et al.

Explore the PTAB proceeding PGR2026-00025 filed by Bicara Therapeutics, Inc. on 2026-02-10. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Proceeding Overview

Proceeding Number

PGR2026-00025

Filing Date

2026-02-10

Accorded Filing Date

2026-02-10

Institution Decision Date

2026-07-14

Last Modified Date

2026-10-16

Proceeding Type

PGR

Termination Date

—

Trial Status

Trial Instituted

Parties & Counsel

Petitioner

Bicara Therapeutics, Inc.

Represented By

Cipriano, Linneaet al

Patent Owner / Respondent

The John Hopkins University et al.

Represented By

Nall, Jenniferet al

Tribunal & Venue

Tribunal

Patent Trial and Appeal Board (USPTO)

Technology Center

TC 1600 - Biotechnology & Organic Chemistry

Patent Information

1 Patent Involved

Respondent Application Number 18883719

Respondent Patent Number 12295968

External Links

Espacenet

Google Patents

Respondent Inventor Atul Bedi et al

Respondent Tech Center TC 1600 - Biotechnology & Organic Chemistry

Address and Attorney/Agent Information

18 Registered Practitioners

Power of Attorney & Correspondence

Firm / Entity Name The John Hopkins University - c/o DLA Piper LLP (US)

Customer Number 100899

Address 4365 Executive Drive, Suite 1100, San Diego, CA, 92121-2133, UNITED STATES

Attorney / Agent Information

Reg #	Name	Phone
36681	Abanti Bhattacharyya	703-681-1732
38347	Lisa Haile	858-677-1456
40116	Elaine Spector	703-259-1056
44628	Joseph Contrera	240-988-8763
50314	Andrea Deering	410-405-6269
52933	Guido Galvez	410-502-9593
54984	Pamela Hwang	858-677-1473
55949	Aldon Griffis	858-638-6756
59051	Larissa Bifano	617-406-6013
65746	Alevtina Zhelonkina	410-516-7789
65881	Andrew Wichmann	202-787-5532
68827	Pierre Santerre Queiroz De Olive	412-454-5878
70092	Roshan Bhattarai	202-799-4418
73844	Jiarong Lamiquiz	650-849-3125
74439	Thomas Fuller	650-324-6357
75410	Gregory Frattini	215-656-3300
79388	Celine Conde	858-677-1422
81026	Alisa Ramakrishnan	215-656-3390

Proceeding Documents

184

ORDER Conduct of Proceeding ORDER

2026-10-16 FILING PARTY: BOARD

Download

PETITIONER’S OBJECTIONS TO PATENT OWNER’S EVIDENCE SUBMITTED WITH PATENT OWNER’S RESPONSE OTHER

2026-10-14 FILING PARTY: PETITIONER

Download

Patent Owner's Unopposed Motion to Withdraw Paper Nos. 16 and 17 MOTION

2026-10-08 FILING PARTY: PATENT OWNER

Download

Patent Owner's Non-Contingent Motion to Amend MOTION

2026-10-06 FILING PARTY: PATENT OWNER

Download

2036

U.S. Patent No. 11,939,387 to Zhang et al. Exhibit

2026-10-06 FILING PARTY: PATENT OWNER

Download

Bicara Therapeutics, Inc. vs. The John Hopkins University et al.

Proceeding Overview

Parties & Counsel

Petitioner

Bicara Therapeutics, Inc. Follow

Represented By

Patent Owner / Respondent

The John Hopkins University et al. Follow

Represented By

Tribunal & Venue

Patent Information

Address and Attorney/Agent Information

Power of Attorney & Correspondence

Attorney / Agent Information

Proceeding Documents

ORDER Conduct of Proceeding ORDER

PETITIONER’S OBJECTIONS TO PATENT OWNER’S EVIDENCE SUBMITTED WITH PATENT OWNER’S RESPONSE OTHER

Patent Owner's Unopposed Motion to Withdraw Paper Nos. 16 and 17 MOTION

Patent Owner's Non-Contingent Motion to Amend MOTION

U.S. Patent No. 11,939,387 to Zhang et al. Exhibit

U.S. Patent Pub. No. 2006/0140889 A1 to Houtzager et al. Exhibit

E-mail authorizing non-contingent motion to cancel claims Exhibit

Kelly Davis Orcutt et al., A modular IgG-scFv bispecific antibody topology, 23 Protein Engineering, Design & Selection 4 Exhibit

U.S. Patent Pub. No. 2009/0252729 A1 to Farrington et al. Exhibit

P. John Hart et al., Crystal structure of the human TßR2 ectodomain-TBF-ß3 complex, 9 NATURE STRUCTURAL BIOLOGY 3 Exhibit

U.S. Patent No. 8,871,912 to Davis et al. Exhibit

GB Patent No. 2,535,753 to Nicholas et al. Exhibit

Jurgen Schänzer et al., Development of Tetravalent, Bispecific CCR5 Antibodies with Antiviral Activity against CCR5 Monoclonal Antibody-Resistant HIV-1 Strains Exhibit

International Patent Pub. No. WO 2012/178137A1 to Gillies et al., titled “Light chain immunoglobulin fusion proteins and methods of use thereof” Exhibit

Expert Declaration of Jonathan Davis, Ph.D., in Support of Patent Owner’s Response to Petition for Post-Grant Review of U.S. Patent No. 12,295,968 Exhibit

Deposition Transcript from Patent Owner’s Deposition of Geoffrey Hale, Ph.D., taken September 29, 2026 Exhibit

Stephen D. Gillies, Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells Exhibit

Patent Owner's Response to Petition for Post-Grant Review of U.S. Patent 12,295,968 RESPONSE

U.S. Patent Pub. No. 2006/0222653 A1 to Abel et al. Exhibit

U.S. Patent No. 9,382,323 to Brinkmann et al. Exhibit

Kristian M. Müller et al., The First Constant Domain (CH1 and CL) of an Antibody Used as Heterodimerization Domain for Bispecific Miniantibodies Exhibit

Curriculum Vitae of Jonathan Davis, Ph.D. Exhibit

E-mail from the Board regarding deposition Exhibit

Patent Owner's Updated Mandatory Notices NOTICE

Exclusive Licensee Y-Trap, Inc.'s Power of Attorney NOTICE

Patent Owner's Notice of Deposition of Geoffrey Hale Ph.D. NOTICE

Petitioner's Objections to Patent Owner's Evidence Submitted with Patent Owner's Preliminary Response OTHER

SCHEDULING ORDER ORDER

EXPUNGED_SCHEDULING ORDER ORDER

Patent Owner's Objections to Preliminary Evidence Submitted by Petitioner OTHER

Institution Decision: Grant DECISION

Director Discretionary Decision: Refer RESPONSE

Exhibit 1101 - Bicara Announces Closing of $362 Million Initial Public Offering Exhibit

Exhibit 1096 - Biocon 2019 Annual Report Exhibit

Exhibit 1108 - Study Record for ClinicalTrials.gov ID NCT06788990 (FORTIFI-HN01) Exhibit

Exhibit 1107 - U.S. FDA - Breakthrough Therapy Exhibit

Exhibit 1109 - Bicara Reports Fourth Quarter and Full Year 2025 Financial Results Exhibit

Exhibit 1104 - Bicara Announces Closing of Oversubscribed Public Offering Exhibit

Exhibit 1099 - Bicara Schedule 14A (April 27, 2026) Exhibit

Exhibit 1097 - Biocon 2021 Annual Report Exhibit

Exhibit 1105 - ClinicalTrials.gov - Bicara Exhibit

Exhibit 1100 - Bicara Amendment No. 3 to Form S-1, (September 11, 2024) Exhibit

Exhibit 1103 - Order re Indian Patent Application No. 8417-CHENP-2012 Exhibit

Petitioner’s Opposition to Patent Owner’s Request for Discretionary Denial RESPONSE

Exhibit 1106 - Bicara Announces Ficerafusp Alfa Granted BTD Exhibit

Exhibit 1098 - Cohlhepp Declaration Exhibit

Exhibit 1102 - Y-Trap Website Exhibit

Feng He et al., High Throughput Thermostability Screening of Monoclonal Antibody Formulations Exhibit

Neil I. Goldstein et al., Biological Efficacy of a Chimeric Antibody to the Epidermal Growth Factor Receptor in a Human Tumor Xenograft Exhibit

FDA Letter Exhibit

Daniela Röthlisberger et al., Domain Interactions in the Fab Fragment Exhibit

Kristian M. Müller et al., The First Constant Domain (CH1 and CL) of an Antibody Used as Heterodimerization Domain for Bispecific Miniantibodies Exhibit

Creative Biolabs, scFv-CH1/CL Exhibit

Gavin C. Barnard et al., High-throughput Screening and Selection of Yeast Cell Lines Expressing Monoclonal Antibodies Exhibit

FDA-Approved Labeling for ERBITUX Exhibit

Patent Owner's Preliminary Response POPR

GenScript, Biology Terms Dictionary Exhibit

John Mendelsohn et al., A Chimeric Antibody, C225, Inhibits EGFR Activation and Tumor Growth Exhibit

Bryan A. Garner, Garner’s Modern English Usage Exhibit

Shareholder, BLACK’S LAW DICTIONARY (12th ed. 2024) Exhibit

Gwendolyn Wu, Two Antibody Startups File for IPOs Amid Summer Slump, BIOPHARMA DIVE (Aug. 23, 2024) Exhibit

Johns Hopkins University, Intellectual Property Policy Exhibit

Johns Hopkins Med., Johns Hopkins Researchers Invent New Technology for Cancer Immunotherapy Exhibit

Grantome: Search Exhibit

Econsult Solutions, Inc., QUANTIFYING THE ECONOMIC FOOTPRINT AND CATALYTIC ROLE OF JOHNS HOPKINS (Oct. 10, 2025) Exhibit

Bicara Therapeutics, Inc.

The John Hopkins University et al.